ID   TU-1
AC   CVCL_M530
DR   cancercelllines; CVCL_M530
DR   Wikidata; Q54973321
RX   CelloPub=CLPUB00455;
RX   PubMed=9249875;
RX   PubMed=10936422;
RX   PubMed=11818668;
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (PubMed=9249875).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   59Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 05-10-23; Version: 13
//
RX   CelloPub=CLPUB00455;
RA   Koskela K., Pelliniemi T.-T., Remes K., Savino R., Ciliberto G.,
RA   Pulkki K.;
RT   "Establishment of three new myeloma cell lines from bone marrow plasma
RT   cells: response to interleukin-6 and interleukin-6-antagonist.";
RL   (In) Vth international workshop on multiple myeloma; pp.3.83-3.83; La Baule (1995).
//
RX   PubMed=9249875; DOI=10.3109/00365519709099401;
RA   Ollikainen H., Syrjanen S.M., Koskela K., Pelliniemi T.-T., Pulkki K.;
RT   "p53 gene mutations are rare in patients but common in
RT   patient-originating cell lines in multiple myeloma.";
RL   Scand. J. Clin. Lab. Invest. 57:281-289(1997).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=11818668; DOI=10.1159/000046625;
RA   Koskela K., Pelliniemi T.-T., Pelliniemi L.J., Remes K.,
RA   Soderstrom K.-O., Punnonen K., Kumar R., Ollikainen H., Pulkki K.;
RT   "Autocrine production and synergistic growth-promoting activity of
RT   interleukin-6 and oncostatin M in a new human myeloma cell line TU-1.";
RL   Acta Haematol. 107:23-28(2002).
//